SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
50753Well if you find that great long-term Asian investment, please share! I do thinBiomaven-2/28/2019
50752OT: Ritholtz talks with Neil Dwayne Allianz Global I have to agree with Dwayne linhtu-2/26/2019
50751The supplement company I use has picked up on the L-Serine topic, too. swansonviOldAIMGuy-2/22/2019
50750Ah ok.. Thanks.. Did not know that..Sultan-2/19/2019
50749Nicotinamide riboside is indeed very interesting as a supplement. Don't knowBiomaven-2/19/2019
50748>>Does not 'open label' mean that every one knows who is getting tBiomaven-2/19/2019
50747OTC supplement show promising results against ALS... In Small Trial, EH301 Appebiocqr-2/19/2019
50746To wrap this up for any one who is interested, here is the company's JanuarySultan-2/19/2019
50745Re: L-Serine & Paul Cox I took an undergrad biology class from Paul Cox. Hejb11822/19/2019
50744Thanks.. Really Appreciate it.. It is obviously now down to the company to proSultan-2/19/2019
50743The caveat as always is that this is proceeding based on a subgroup analysis. StBiomaven-2/19/2019
50742Any comments, observation ? Thanks. Spectral Announces Approval of Tigris TrialSultan-2/19/2019
50741very interesting read (the first one haven't looked at this), can't hurtoldirtybastard-2/19/2019
50740Some more papers on this L-serine idea: https://twitter.com/Biomaven/status/109Biomaven-2/18/2019
50739first gene therapy patient for wAMD has been recently dosed as well investors.aoldirtybastard-2/18/2019
50738AMD (both the dry and wet forms) are multifaceted diseases. I doubt that any sinDewDiligence_on_SI12/18/2019
50737First gene therapy treatment for AMD, bbc.co.uk The trial is on dry AMD, the moA.J. Mullen12/18/2019
50736Someone actually sent that article to me already. It's out there, but not crBiomaven-2/18/2019
50735From Fortune: “Could This Radical New Approach to Alzheimer’s Lead to a BreakthrBulbaMan-2/17/2019
50734educational resources via bms: pick either healthcare professionals or patientssoftware salesperson-2/15/2019
50733Well the effect of a failure is twofold - removes competition but also reinforceBiomaven-2/14/2019
50732Talking of Gileads failure in Nash, finance.yahoo.com , the prices of the competA.J. Mullen-2/14/2019
50731 Avedro$AVDR What do folks think about Avedro ($AVDR) seems like an interestingCC007-2/14/2019
50730An interesting study, which might re-inforce the case for small biotechs: theatlnigel bates12/14/2019
50729NASH isn't an area I've paid much attention to, but this viewpoint from jb118-2/12/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News